Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Bird flu vaccine development is moving faster than ever. From FDA fast track designation to breakthrough nasal spray technology, here are the latest developments in the race to prepare for a potential H5N1 pandemic — and the expanded safety monitoring that would come with it.
In January 2026, the FDA granted fast track designation to ARCT-2304, a self-amplifying mRNA (saRNA) vaccine developed by Arcturus Therapeutics for prevention of H5N1 avian influenza. This designation provides several regulatory advantages: more frequent FDA meetings during development, eligibility for rolling review (submitting data as it becomes available rather than waiting for a complete package), and potential priority review.
What makes self-amplifying mRNA different from standard mRNA vaccines like Moderna's? The saRNA approach includes a replicase gene that allows the mRNA to copy itself inside cells, potentially producing more antigen protein from a smaller initial dose. This could mean lower doses produce equivalent immune responses — a significant advantage when vaccine supply needs to stretch across a large population quickly.
Published in February 2026, research on a novel nasal spray H5N1 vaccine demonstrated results that could reshape avian influenza vaccination strategy. The vaccine uses an influenza virus vector-based platform — originally pioneered during the COVID-19 pandemic — to deliver H5N1 antigens directly to the nasal mucosa.
Why does the delivery route matter? Traditional injected vaccines primarily stimulate systemic immunity (antibodies in the blood), while nasal vaccines can generate mucosal IgA antibodies at the site where respiratory viruses enter the body. In animal studies, the nasal spray provided stronger protection than traditional intramuscular flu shots, suggesting it could both prevent infection and reduce viral shedding — potentially limiting transmission.
University of Nebraska–Lincoln researchers published results in April 2026 showing a vaccine approach that protected both mice and dairy calves against highly pathogenic H5N1 — a first for bird flu. The significance: H5N1's unprecedented spread through U.S. dairy cattle has created a massive animal reservoir that increases spillover risk to humans. A vaccine that protects cattle would reduce the virus's foothold in the food supply while simultaneously serving as a human vaccine candidate.
The researchers are seeking funding and industry partnerships to advance the multispecies vaccine through further evaluation. If successful, this approach could protect both agricultural workers and the animals they work with — addressing the outbreak at its source.
Moderna's mRNA-1018 H5N1 vaccine, which entered Phase 2/3 trials in mid-2025 with approximately 6,000 participants, continues to advance. Early data showed strong neutralizing antibody responses after a single dose with a safety profile consistent with other mRNA vaccines. By May 2026, an mRNA-based bird flu vaccine was being trialed specifically in high-risk groups including poultry workers and older adults.
Notably, the original $590 million HHS contract with Moderna for H5N1 vaccine development, issued in January 2025, was terminated by May 2025. However, Moderna has continued development through other funding mechanisms, reflecting the company's assessment that pandemic preparedness vaccines represent a significant commercial opportunity.
A less-noticed but significant development: on May 8, 2025, the CDC and FDA expanded public access to VAERS data through the WONDER database and downloadable files. The enhancement provides a more complete picture of all reported adverse events following vaccination, including expanded access to secondary reports and more detailed data fields.
This matters for H5N1 because any deployed bird flu vaccine would be monitored through these enhanced systems. The infrastructure for post-market safety surveillance is substantially more mature than it was at the start of COVID-19 vaccination in late 2020. VaccineWatch will provide full VAERS data exploration for any H5N1 vaccine as reports become available.
As of July 2026, H5N1 clade 2.3.4.4b continues to circulate in U.S. dairy cattle (940+ affected herds across 30+ states), wild birds, and poultry flocks across 87 countries globally. The CDC streamlined A(H5) bird flu updates with routine influenza data reporting in July 2025, reflecting the ongoing but stable nature of the public health situation.
The risk assessment remains: current risk to the general public is low, but the virus's continued circulation in mammalian hosts creates ongoing pandemic potential. Vaccination remains the primary preparedness tool, which is why development is proceeding urgently even without active human-to-human transmission.